Balaji Prasad
Stock Analyst at Barclays
(3.55)
# 884
Out of 5,091 analysts
132
Total ratings
49.19%
Success rate
5.31%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.97 | +258.68% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $11.87 | -7.33% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $24.42 | -1.72% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $11.09 | -18.85% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $168.94 | +18.39% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $21.69 | -12.40% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $82.23 | -27.03% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $118.16 | +106.50% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $7.29 | +229.22% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $40.08 | -45.11% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $706.65 | -26.41% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $28.33 | -8.22% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.89 | +22.39% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $5.45 | +230.28% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.98 | +151.26% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.28 | +446.88% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.97
Upside: +258.68%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $11.87
Upside: -7.33%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $24.42
Upside: -1.72%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $11.09
Upside: -18.85%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $168.94
Upside: +18.39%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $21.69
Upside: -12.40%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $82.23
Upside: -27.03%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $118.16
Upside: +106.50%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $7.29
Upside: +229.22%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $40.08
Upside: -45.11%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $706.65
Upside: -26.41%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $28.33
Upside: -8.22%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.89
Upside: +22.39%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $5.45
Upside: +230.28%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.98
Upside: +151.26%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.28
Upside: +446.88%